NCAM,APP And Aβ Used To Alzheimer Disease Diagnosis As Biomarkers

Objective:The study based on the earlier research that the amyloid precursor protein, (APP) and neural cell adhesion molecule (NCAM) interaction, the serum APP, NCAM and β-amyloid(Aβ) level can be used to diagnose Alzheimer disease(AD). And APP and NCAM interaction in MAPK signaling pathway. Methods:Serum samples of clinical AD patients and healthy donors were collected. The levels of APP, NCAM, Aβ40 and AP42 were detected by ELISA methods, and the differences between two groups were observed. Plasmids harboring NCAM 140 or APP gene was transfected to HEK293 cells. Gene expression profile PCR chip was used to investigate the APP and NCAM interaction in MAPK signaling pathway. Results: Serum APP(P<0.01) and NCAM(P<0.01) concentration of AD patients is significantly higher than that of control group. Aβ40 is far more than Aβ42, and Aβ42 concentration of AD patients is significantly higher than that of control group(P<0.01). There is a high positive association between APP and Aβ40 (r=0.731 P<0.01) or Aβ42 (r=0.735 P<0.01). A low negative association between NCAM and Aβ40 (r=-0.472 P<0.01) or Aβ42 (r=-0.338 P<0.01) was observed. In MAPK signaling pathways, FASLG was found to be apparently high expression after plasmid transfected to HEK293. Conclusions:Serum APP, NCAM and AP level can be used to diagnose AD. Maybe NCAM can inhibit the production of Aβ40 and Aβ42 by combined with APP extracellular, and some small molecule drugs can be designed to intervene in AD early stage. Interaction between APP and NCAM may be regulated and controlled by FASLG and relative molecules in signaling pathways to play biological functions. These data provides useful evidences for further research.